Baseline characteristics of patients randomly assigned to RT vs OBS
| Factors . | RT . | OBS . | Total . |
|---|---|---|---|
| (n = 58) . | (n = 58) . | (n = 116) . | |
| Age, median (IQR) | 31.50 (26.00-39.75) | 29.50 (25.00-37.00) | 31.00 (25.00-39.00) |
| Sex | |||
| Male | 34 (59) | 30 (52) | 64 (55) |
| Female | 24 (41) | 28 (48) | 52 (45) |
| IPS | |||
| 0-2 | 33 (57) | 35 (60) | 68 (59) |
| ≥3 | 25 (43) | 22 (40) | 48 (41) |
| Histology | |||
| NS | 38 (66) | 39 (67) | 77 (66) |
| MC | 11 (19) | 5 (9) | 16 (14) |
| LD | 1 (2) | 3 (5) | 4 (3) |
| LR | 2 (3) | 5 (9) | 7 (6) |
| NA | 6 (10) | 6 (10) | 12 (10) |
| B symptoms | |||
| No | 14 (24) | 21 (36) | 35 (30) |
| Yes | 44 (76) | 37 (64) | 81 (70) |
| ECOG PS | |||
| 0 | 35 (60) | 38 (66) | 73 (63) |
| 1 | 16 (28) | 17 (29) | 33 (28) |
| 2 | 7 (12) | 3 (5) | 10 (9) |
| Stage | |||
| 2 | 19 (33) | 15 (26) | 34 (29) |
| 3 | 21 (36) | 20 (34) | 41 (35) |
| 4 | 18 (31) | 23 (40) | 41 (35) |
| Extranodal lesion sites | |||
| 0 | 39 (67) | 34 (59) | 73 (63) |
| ≥1 | 19 (33) | 24 (41) | 43 (37) |
| Involved nodal sites, median (IQR) | 6.00 (4.00-8.75) | 6.00 (4.00-8.00) | — |
| Number of bulky lesion sites | |||
| 1 | 52 (90) | 48 (83) | 100 (86) |
| 2 | 5 (9) | 6 (10) | 11 (9) |
| 3 | 1 (2) | 3 (5) | 4 (3) |
| 4 | 0 (0) | 1 (2) | 1 (1) |
| Bulky lesion site | |||
| Mediastinum | 41 (71) | 39 (67) | 80 (69) |
| Other sites | 17 (29) | 19 (33) | 36 (31) |
| Bulky site size, cm | |||
| <7 | 19 (33) | 18 (31) | 37 (32) |
| 7-10 | 16 (28) | 19 (33) | 35 (30) |
| ≥10 | 23 (40) | 21 (36) | 44 (38) |
| Factors . | RT . | OBS . | Total . |
|---|---|---|---|
| (n = 58) . | (n = 58) . | (n = 116) . | |
| Age, median (IQR) | 31.50 (26.00-39.75) | 29.50 (25.00-37.00) | 31.00 (25.00-39.00) |
| Sex | |||
| Male | 34 (59) | 30 (52) | 64 (55) |
| Female | 24 (41) | 28 (48) | 52 (45) |
| IPS | |||
| 0-2 | 33 (57) | 35 (60) | 68 (59) |
| ≥3 | 25 (43) | 22 (40) | 48 (41) |
| Histology | |||
| NS | 38 (66) | 39 (67) | 77 (66) |
| MC | 11 (19) | 5 (9) | 16 (14) |
| LD | 1 (2) | 3 (5) | 4 (3) |
| LR | 2 (3) | 5 (9) | 7 (6) |
| NA | 6 (10) | 6 (10) | 12 (10) |
| B symptoms | |||
| No | 14 (24) | 21 (36) | 35 (30) |
| Yes | 44 (76) | 37 (64) | 81 (70) |
| ECOG PS | |||
| 0 | 35 (60) | 38 (66) | 73 (63) |
| 1 | 16 (28) | 17 (29) | 33 (28) |
| 2 | 7 (12) | 3 (5) | 10 (9) |
| Stage | |||
| 2 | 19 (33) | 15 (26) | 34 (29) |
| 3 | 21 (36) | 20 (34) | 41 (35) |
| 4 | 18 (31) | 23 (40) | 41 (35) |
| Extranodal lesion sites | |||
| 0 | 39 (67) | 34 (59) | 73 (63) |
| ≥1 | 19 (33) | 24 (41) | 43 (37) |
| Involved nodal sites, median (IQR) | 6.00 (4.00-8.75) | 6.00 (4.00-8.00) | — |
| Number of bulky lesion sites | |||
| 1 | 52 (90) | 48 (83) | 100 (86) |
| 2 | 5 (9) | 6 (10) | 11 (9) |
| 3 | 1 (2) | 3 (5) | 4 (3) |
| 4 | 0 (0) | 1 (2) | 1 (1) |
| Bulky lesion site | |||
| Mediastinum | 41 (71) | 39 (67) | 80 (69) |
| Other sites | 17 (29) | 19 (33) | 36 (31) |
| Bulky site size, cm | |||
| <7 | 19 (33) | 18 (31) | 37 (32) |
| 7-10 | 16 (28) | 19 (33) | 35 (30) |
| ≥10 | 23 (40) | 21 (36) | 44 (38) |
Data are expressed as the number of patients (percentage of subgroup or total), unless otherwise stated. ECOG PS, Eastern Cooperative Oncology Group performance status; LD, lymphocyte depleted; LR, lymphocyte rich; MC, mixed cellularity’ NA, not available; NS, nodular sclerosis.